Evidence map›Paper›PMID 41891922›Full record

ArticleThe Journal of experimental medicine2026

TIE2 links MEKK3-KLF2/4 and PI3K signaling in cerebral cavernous malformation.

Lun Li, Marco Castro, Hiroki Hongo, Jian Ren, Robert Shenkar, Rashad Jabarkheel, Siqi Gao, Sweta Narayan, Maxwell Frankfurter, Alan T Tang and 17 more

Abstract read
In one paragraph

Article in The Journal of experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Lun LiCardiovascular Institute and Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0003-2697-8296
Marco CastroAngiogenesis & Metabolism Laboratory, Center of Vascular Biomedicine, Berlin Institute of Health at Charité - Universitätsmedizin Berlin , Berlin, Germany.ORCID 0000-0001-7851-7446
Hiroki HongoCardiovascular Institute and Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0009-0001-8594-091X
Jian RenCardiovascular Institute and Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0003-2478-6653
Robert ShenkarDepartment of Surgery, Neurovascular Surgery Program, Section of Neurosurgery, Medicine and Biological Sciences, The University of Chicago, Chicago, IL, USA.ORCID 0000-0002-1300-6845
Rashad JabarkheelCardiovascular Institute and Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0002-7643-2622
Siqi GaoCardiovascular Institute and Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0002-6504-4536
Sweta NarayanCardiovascular Institute and Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0002-8923-617X
Maxwell FrankfurterCardiovascular Institute and Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0002-4370-4556
Alan T TangCardiovascular Institute and Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0003-1422-0349
Jisheng YangCardiovascular Institute and Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0009-0000-5449-8789
Mei ChenCardiovascular Institute and Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0001-7761-8835
Jenna BockmanCardiovascular Institute and Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0009-0009-1013-4655
Patricia Mericko-IshizukaCardiovascular Institute and Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0001-9891-4588
Roberto AlcazarDepartment of Surgery, Neurovascular Surgery Program, Section of Neurosurgery, Medicine and Biological Sciences, The University of Chicago, Chicago, IL, USA.ORCID 0000-0003-1214-5576
Georgio SaderDepartment of Surgery, Neurovascular Surgery Program, Section of Neurosurgery, Medicine and Biological Sciences, The University of Chicago, Chicago, IL, USA.ORCID 0009-0007-6402-9493
Javed IqbalDepartment of Surgery, Neurovascular Surgery Program, Section of Neurosurgery, Medicine and Biological Sciences, The University of Chicago, Chicago, IL, USA.ORCID 0000-0002-3732-547X
Serena KinkadeDepartment of Surgery, Neurovascular Surgery Program, Section of Neurosurgery, Medicine and Biological Sciences, The University of Chicago, Chicago, IL, USA.ORCID 0009-0005-0403-4931
Rhonda LightleDepartment of Surgery, Neurovascular Surgery Program, Section of Neurosurgery, Medicine and Biological Sciences, The University of Chicago, Chicago, IL, USA.ORCID 0000-0003-2760-195X
Andrew K ResslerDepartment of Molecular Genetics and Microbiology, School of Medicine, Duke University, Durham, NC, USA.ORCID 0000-0001-5481-2774
Xianghu QuDivision of Pediatrics Cardiology, Department of Cell and Developmental Biology, Vanderbilt University, Nashville, TN, USA.ORCID 0000-0003-1701-812X
H Scott BaldwinDivision of Pediatrics Cardiology, Department of Cell and Developmental Biology, Vanderbilt University, Nashville, TN, USA.ORCID 0000-0002-9880-1732
Douglas A MarchukDepartment of Molecular Genetics and Microbiology, School of Medicine, Duke University, Durham, NC, USA.ORCID 0000-0002-3110-6671
Issam A AwadDepartment of Surgery, Neurovascular Surgery Program, Section of Neurosurgery, Medicine and Biological Sciences, The University of Chicago, Chicago, IL, USA.ORCID 0000-0003-1510-602X
Jan-Karl BurkhardtDepartment of Neurosurgery, Perelman School of Medicine, Hospital of the University of Pennsylvania, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0001-8381-0313
Michael PotenteAngiogenesis & Metabolism Laboratory, Center of Vascular Biomedicine, Berlin Institute of Health at Charité - Universitätsmedizin Berlin , Berlin, Germany.ORCID 0000-0002-5689-0036
Mark L KahnCardiovascular Institute and Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0002-6489-7086

Funding

Somatic mutation(s) and cellular changes in CCM pathogenesisP01NS092521 · NINDS · DUKE UNIVERSITY · PI KAHN, MARK L · 2015 to 2024
$12.9M
Heg-CCM Signaling in Cardiovascular Development and DiseaseR01HL094326 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI KAHN, MARK L · 2009 to 2018
$3.5M
TLR4 and the microbiome in CCM diseaseR01NS100949 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI KAHN, MARK L · 2017 to 2021
$2.8M
Adelman CCMAHA Postdoctoral Fellowship 906488Deutsche Forschungsgemeinschaft SFB 1531 - 456687919German Center for Cardiovascular ResearchLeducq FoundationNHLBI NIH HHS R01 HL094326NIH HHS P01NS092521NIH HHS R01HL094326NIH HHS R01NS100949NINDS NIH HHS P01 NS092521NINDS NIH HHS R01 NS100949
6 · The paper itself

Abstract

Cerebral cavernous malformations (CCMs) are vascular lesions in the central nervous system that can cause strokes and seizures. Aggressive CCM growth follows an endothelial cell two-hit mechanism in which enhanced MEKK3-KLF2/4 signaling stimulates PI3K signaling, but how these pathways are linked has been undefined. Here, we use human CCM specimens, two mouse models of CCM disease, and primary human endothelial cells to examine the roles of the major endothelial growth factor receptors, VEGFR2 and TIE2. We find no evidence of augmented VEGFR2 signaling in CCM lesions, and neither genetic nor pharmacologic blockade of VEGFR2 reduced CCM formation in mouse models. Instead, we observe markedly increased phospho-TIE2 levels in human and mouse CCM lesions, MEKK3-KLF2/4-driven induction of TIE2 receptor expression, and almost complete rescue of CCM formation following genetic or pharmacologic TIE2 blockade in mouse models. Our studies identify TIE2 as the molecular link between the MEKK3-KLF2/4 and PI3K signaling pathways during CCM formation and suggest that targeting TIE2 may be an effective means to treat human CCM disease.

Indexed as

Hemangioma, Cavernous, Central Nervous SystemKruppel-Like Transcription FactorsMAP Kinase Kinase Kinase 3Phosphatidylinositol 3-KinasesReceptor, TIE-2Signal TransductionAnimalsDisease Models, AnimalEndothelial CellsHumansKruppel-Like Factor 4MiceVascular Endothelial Growth Factor Receptor-2KLF2 protein, humanKlf2 protein, mouseKLF4 protein, humanKlf4 protein, mouseKruppel-Like Factor 4Kruppel-Like Transcription FactorsMAP3K3 protein, humanMap3k3 protein, mouseMAP Kinase Kinase Kinase 3Phosphatidylinositol 3-KinasesReceptor, TIE-2TEK protein, humanVascular Endothelial Growth Factor Receptor-2

Identifiers

PMID41891922
PMCPMC13459978

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.